22/05/2026
1 in 7 people in the UK live with migraine, but for years many had exhausted every available treatment with little relief.
That's changing.
Since NICE recommended atogepant and rimegepant, the first migraine-prevention tablets of their kind, prescriptions have more than tripled in a year. In 2025, 22,800 people received these medicines through their GP alone.
Migraines can last days, affect work, mental health and relationships, and cost the UK economy up to £9 billion a year. These tablets work differently from older preventative treatments, targeting the chemical directly associated with migraine attacks.
🔗 Read the data story: https://www.nice.org.uk/news/articles/more-than-20-000-people-benefitting-from-innovative-migraine-pills-recommended-by-nice?utm_medium=organic&utm_source=facebook&utm_campaign=migrane_date&utm_content=graphic